Donor Screening for Fecal Microbiota Transplantation in China: Evaluation of 8483 Candidates

Zhang, Shaoyi; Chen, Qiyi; Kelly, Colleen R.; Kassam, Zain; Qin, Huanlong; Li, Ning; Tian, Hongliang; Yang, Bo; Zhao, Di; Wang, Hongzhi; Lin, Zhiliang Caleb; Cui, Jiaqu; Zhou, Shen; Xia, Chen; Lv, Xiaoqiong; Yang, Rong

doi:10.1053/j.gastro.2021.11.004

Cited by 13 publications

(15 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 These strategies have been adopted by different institutions. [24][25][26][27] The number of qualified donors declined significantly under this strict protocol. 25,27 Khanna et al reported a protocol for COVID-19 symptom assessment every 2 weeks for all donors and serology tests for anti-SARS-CoV-2 IgG or PCR on nasopharyngeal swab every 2 weeks for donors and recipients.…”

Section: Discussionmentioning

confidence: 99%

“…[24][25][26][27] The number of qualified donors declined significantly under this strict protocol. 25,27 Khanna et al reported a protocol for COVID-19 symptom assessment every 2 weeks for all donors and serology tests for anti-SARS-CoV-2 IgG or PCR on nasopharyngeal swab every 2 weeks for donors and recipients. 24 Although the protocol was applied only on a small number of donors, it presented a safety profile for FMT.…”

Section: Discussionmentioning

confidence: 99%

“…Furthermore, some centers in China had protocols of bacterial composition assessment via stool sequencing during the screening process. 27,30 Although the COVID-19 seems to have ended, there are still possibilities of emerging infectious diseases in the future. The ways in which infectious diseases spread vary.…”

Section: Discussionmentioning

confidence: 99%

“…Strategies for SARS‐CoV‐2 screening included a standard questionnaire on clinical exposure and symptoms of COVID‐19, nasopharyngeal swab and serology for SARS‐CoV2 at recruitment, and periodic questionnaires and rapid stool tests for SARS‐CoV‐2 at serial donations 7 . These strategies have been adopted by different institutions 24–27 . The number of qualified donors declined significantly under this strict protocol 25,27 .…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Assuring safety of fecal microbiota transplantation in the COVID‐19 era: A single‐center experience

Chang,

Lee,

Lee

et al. 2023

JGH Open

View full text Add to dashboard Cite

Background and AimFecal microbiota transplantation (FMT) is used to treat recurrent or refractory Clostridioides difficile infection (CDI). In the past, screening of fecal donors required surveillance of personal behavior, medical history, and diseases that could be transmitted by the blood or fecal–oral route. In addition, the exclusion of multidrug‐resistant organisms (MDROs) has been recommended since 2018. This task has become more complicated in the era of the coronavirus disease‐2019 (COVID‐19) pandemic. To prevent fecal transmission of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), it is crucial to commence screening for SARS‐CoV‐2, alongside other traditional tests. Our aim was to investigate whether hidden carriers of SARS‐CoV‐2 were enrolled for stool donation, and the status of the presence or incidence of MDRO during fecal donation in Taiwan.MethodsFecal products collected from March 2019 to December 2022 were tested for MDRO and nucleic acid amplification tests for SARS‐CoV‐2 using the pooling method. The period of fecal product collection crossed the time before and during the COVID pandemic in Taiwan.ResultsA total of 151 fecal samples were collected. The fecal products were tested using polymerase chain reaction (PCR) to detect SARS‐CoV‐2. The results were negative for all stocks. This was similar to the results of MDRO testing. The safety of FMT products has been guaranteed during the pandemic.ConclusionOur FMT center produced MDRO‐free and COVID‐19‐free products before and during the COVID‐19 outbreak in Taiwan. Our protocol was effective for ensuring the safety of FMT products.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Assuring safety of fecal microbiota transplantation in the COVID‐19 era: A single‐center experience

Chang,

Lee,

Lee

et al. 2023

JGH Open

View full text Add to dashboard Cite

show abstract

“…With the increasing knowledge of the gut microbiome impacting ASD, gut microbiota modulation to restore gut microbial homeostasis has become a potential strategy for ASD treatment. In particular, fecal microbiota transplantation (FMT) has been proposed to be a safe and efficient strategy to adjust GI microbiota symbiosis and improve behavior symptoms for ASD children [ 7 , 8 ]. Although the gut microbiome emerges as an integral player in gut-brain communication [ 9 – 11 ], there is still much that remains unknown about the brain-gut-microbiome axis in ASD, especially the effect of specific microbiota and their function on ASD development and/or the improvement in ASD-associated behaviors.…”

Section: Introductionmentioning

confidence: 99%

Fecal microbiota transplantation improves VPA-induced ASD mice by modulating the serotonergic and glutamatergic synapse signaling pathways

et al. 2023

Self Cite

View full text Add to dashboard Cite

Autism spectrum disorder (ASD) is a complex behavioral disorder diagnosed by social interaction difficulties, restricted verbal communication, and repetitive behaviors. Fecal microbiota transplantation (FMT) is a safe and efficient strategy to adjust gut microbiota dysbiosis and improve ASD-related behavioral symptoms, but its regulatory mechanism is unknown. The impact of the microbiota and its functions on ASD development is urgently being investigated to develop new therapeutic strategies for ASD. We reconstituted the gut microbiota of a valproic acid (VPA)-induced autism mouse model through FMT and found that ASD is in part driven by specific gut dysbiosis and metabolite changes that are involved in the signaling of serotonergic synapse and glutamatergic synapse pathways, which might be associated with behavioral changes. Further analysis of the microbiota showed a profound decrease in the genera Bacteroides and Odoribacter, both of which likely contributed to the regulation of serotonergic and glutamatergic synapse metabolism in mice. The engraftment of Turicibacter and Alistipes was also positively correlated with the improvement in behavior after FMT. Our results suggested that successful transfer of the gut microbiota from healthy donors to ASD mice was sufficient to improve ASD-related behaviors. Modulation of gut dysbiosis by FMT could be an effective approach to improve ASD-related behaviors in patients.

show abstract

Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy

Zhuang,

Liang,

et al. 2024

MedComm

View full text Add to dashboard Cite

Autism spectrum disorder (ASD) has become a common neurodevelopmental disorder. The heterogeneity of ASD poses great challenges for its research and clinical translation. On the basis of reviewing the heterogeneity of ASD, this review systematically summarized the current status and progress of pathogenesis, diagnostic markers, and interventions for ASD. We provided an overview of the ASD molecular mechanisms identified by multi‐omics studies and convergent mechanism in different genetic backgrounds. The comorbidities, mechanisms associated with important physiological and metabolic abnormalities (i.e., inflammation, immunity, oxidative stress, and mitochondrial dysfunction), and gut microbial disorder in ASD were reviewed. The non‐targeted omics and targeting studies of diagnostic markers for ASD were also reviewed. Moreover, we summarized the progress and methods of behavioral and educational interventions, intervention methods related to technological devices, and research on medical interventions and potential drug targets. This review highlighted the application of high‐throughput omics methods in ASD research and emphasized the importance of seeking homogeneity from heterogeneity and exploring the convergence of disease mechanisms, biomarkers, and intervention approaches, and proposes that taking into account individuality and commonality may be the key to achieve accurate diagnosis and treatment of ASD.

show abstract

Donor Screening for Fecal Microbiota Transplantation in China: Evaluation of 8483 Candidates

Cited by 13 publications

References 13 publications

Assuring safety of fecal microbiota transplantation in the COVID‐19 era: A single‐center experience

Assuring safety of fecal microbiota transplantation in the COVID‐19 era: A single‐center experience

Fecal microbiota transplantation improves VPA-induced ASD mice by modulating the serotonergic and glutamatergic synapse signaling pathways

Autism spectrum disorder: pathogenesis, biomarker, and intervention therapy

Contact Info

Product

Resources

About